Posted by Michael Wonder on 01 Feb 2024
Ivosidenib for the treatment of patients with advanced IDH1 R132 mutation positive cholangiocarcinoma after one or more systemic treatments
31 January 2024 - NICE has published final evidence-based recommendations on the use of ivosidenib (Tibsovo) for the treatment of patients with locally advanced or metastatic IDH1 R132 mutation positive cholangiocarcinoma after one or more systemic treatments.
Ivosidenib is recommended as an option for the treatment of adults with locally advanced or metastatic IDH1 R132 mutation positive cholangiocarcinoma after one or more systemic treatments only recommended if Servier provides it according to the commercial arrangement.
